Recognize and assess inadequate responses to antidepressants in patients with MDD and determine when adjunctive treatment is warranted Evaluate the mechanisms of action and latest clinical data associated with FDA-approved and emerging atypical antipsychotics for adjunctive treatment of MDD Implement strategies for selecting among adjunctive atypical antipsychotics and overcoming barriers to their optimal use in MDD
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1.25 credits
- MOC · Up to 1.25 points
- Commercial Support
-
ReleasedOct 30, 2025
-
Last day to claim creditOct 31, 2026 3 weeks left
-
HMP Education Beyond Partial Response: Functional and Remission-Based Strategies in MDD
-
HMP Education Aiming Higher in MDD: Practical Strategies and Novel Monotherapies to Improve Outcomes
-
HMP Education Antidepressants for Older Adults with MDD: Integrating Clinical and Real-World Evidence with Patient-Specific Considerations to Optimize Outcomes
